NextPharma Technologies has sold Bioserv Corp., its U.S. affiliate in San Diego, to KESA Partners, Inc. NextPharma plans to focus on its core specialty and conventional product and technology platform in Europe, as well as expand its sales and marketing presence in North America. Bioserv provides contract manufacturing and packaging services to the pharma/biopharma industry.
 
Al Hansen, managing partner at KESA Partners, said, “This is an exciting time for Bioserv. For almost 20 years, Bioserv has been known for its quality, flexibility and responsiveness to customers’ unique requirements. Bioserv is well positioned to benefit from increased outsourcing in the pharma industry. Bioserv has a strong foundation to build upon and to add capabilities to its current service offering. By enhancing our capabilities and emphasizing excellence in quality and execution, Bioserv will become a leader in the contract manufacturing space.”
 
Franck Latrille, chief executive officer, NextPharma, said, “The divestment of Bioserv represents a successful step in the implementation of NextPharma’s strategy, enabling us to focus our growth strategy on NextPharma’s core strengths and areas of expertise. I would like to thank Bioserv’s employees for their efforts and contributions over the past years, and I wish each of them, as well as Bioserv’s customers and new owners, a successful future.”